Wednesday, November 4, 2026

The Andersons And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

October 8, 2021

The Andersons  And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - The Andersons (ANDE), Leidos Holdings (LDOS), CONMED Corporation (CNMD) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. The Andersons (ANDE)

19.1% sales growth and 4.37% return on equity

The Andersons, Inc., an agriculture company, operates in trade, ethanol, plant nutrient, and rail sectors in the United States and internationally.

The Andersons's sales growth this year is expected to be 41.2% and 2.3% for next year.

Year-on-year quarterly revenue growth grew by 42.2%, now sitting on 8.99B for the twelve trailing months.

Volume

Today's last reported volume for The Andersons is 60807 which is 57.83% below its average volume of 144206.

The Andersons's sales growth for the next quarter is 19.1%. The company's growth estimates for the current quarter and the next is a negative 28.6% and 16.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.37%.

Volatility

The Andersons's last day, last week, and last month's current volatility was 2.14%, 1.74%, and 1.30%, respectively.

The Andersons's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.03% (day), 2.65% (last week), and 2.81% (last month), respectively.

The Andersons's Stock Yearly Top and Bottom Value

The Andersons's stock is valued at $31.43 at 06:22 EST, below its 52-week high of $34.41 and way above its 52-week low of $18.02.

The Andersons's Moving Average

The Andersons's worth is above its 50-day moving average of $30.02 and higher than its 200-day moving average of $29.40.

2. Leidos Holdings (LDOS)

11.7% sales growth and 19.1% return on equity

Leidos Holdings, Inc. provides services and solutions in the defense, intelligence, civil, and health markets in the United States and internationally.

Leidos Holdings's sales growth this year is expected to be 13.9% and 7% for next year.

Year-on-year quarterly revenue growth grew by 18.3%, now sitting on 13.26B for the twelve trailing months.

Volume

Today's last reported volume for Leidos Holdings is 490679 which is 36.02% below its average volume of 767036.

Leidos Holdings's sales growth for the next quarter is 11.7%. The company's growth estimates for the present quarter and the next is 9.5% and 1.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.1%.

Volatility

Leidos Holdings's last day, last week, and last month's current volatility was 1.35%, 1.54%, and 1.46%, respectively.

Leidos Holdings's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.40% (day), 2.33% (last week), and 1.96% (last month), respectively.

Leidos Holdings's Stock Yearly Top and Bottom Value

Leidos Holdings's stock is valued at $97.43 at 06:22 EST, way under its 52-week high of $113.75 and way higher than its 52-week low of $79.15.

Leidos Holdings's Moving Average

Leidos Holdings's value is above its 50-day moving average of $96.38 and under its 200-day moving average of $100.49.

3. CONMED Corporation (CNMD)

11.6% sales growth and 7.63% return on equity

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide.

CONMED Corporation's sales growth this year is expected to be 18.8% and 9.1% for next year.

Year-on-year quarterly revenue growth grew by 61.7%, now sitting on 978.5M for the twelve trailing months.

Volume

Today's last reported volume for CONMED Corporation is 203609 which is 8.59% below its average volume of 222765.

CONMED Corporation's sales growth is a negative 0% for the current quarter and 11.6% for the next. The company's growth estimates for the current quarter and the next is a negative 14.8% and 29.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.63%.

Volatility

CONMED Corporation's last day, last week, and last month's current volatility was 2.87%, 1.48%, and 1.38%, respectively.

CONMED Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.16% (day), 3.33% (last week), and 2.81% (last month), respectively.

CONMED Corporation's Stock Yearly Top and Bottom Value

CONMED Corporation's stock is valued at $129.86 at 06:22 EST, way under its 52-week high of $146.95 and way higher than its 52-week low of $76.43.

CONMED Corporation's Moving Average

CONMED Corporation's value is above its 50-day moving average of $129.38 and below its 200-day moving average of $133.35.

4. Discovery Inc (DISCA)

10.1% sales growth and 9.5% return on equity

Discovery, Inc. operates as a media company in the United States and internationally.

Discovery Inc's sales growth this year is expected to be 14% and 4.4% for next year.

Year-on-year quarterly revenue growth grew by 4.1%, now sitting on 10.78B for the twelve trailing months.

Volume

Today's last reported volume for Discovery Inc is 6703320 which is 21.27% above its average volume of 5527220.

Discovery Inc's sales growth for the next quarter is 10.1%. The company's growth estimates for the present quarter and the next is a negative 51.9% and 14.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.5%.

Volatility

Discovery Inc's last day, last week, and last month's current volatility was 1.42%, 3.68%, and 1.91%, respectively.

Discovery Inc's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.68% (day), 2.58% (last week), and 2.79% (last month), respectively.

Discovery Inc's Stock Yearly Top and Bottom Value

Discovery Inc's stock is valued at $26.46 at 06:22 EST, way below its 52-week high of $78.14 and way higher than its 52-week low of $19.07.

Discovery Inc's Moving Average

Discovery Inc's worth is below its 50-day moving average of $26.97 and way under its 200-day moving average of $32.54.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Moves Into Devices, Security and Platforms: Physical AI Data, On-Device Compute and Agent Governance Drive a Late-October Product Wave
In late October 2026, vendors across hardware, enterprise software and security launched products built around AI moving out of the cloud and into devices, workflows and physical systems. Examples include NVIDIA RTX Spark laptops with Adobe, ASUS and Windows support for local and hybrid AI, and Harvest Praxis and Encord on embodied or physical AI. Enterprise software and security vendors (Salesforce–Braze, Fortinet, ServiceNow, Cisco, Intuit) are consolidating AI-driven customer data, adding inline AI security and agent governance, and embedding AI in financial and accounting workflows. The finance link is indirect: it rests on M&A, fintech-adjacent AI tooling and the capital flowing into physical AI. No regulatory driver appears in the facts.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,548 source documents archived
Query this data → isubstrate.com